Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Introduction Postmenopausal osteoporosis (PMOP), as a systemic disease of osteoporosis type, is typified by bone loss as well as increased risks of fracture, primarily on account of the significant decline in estrogen levels after menopause [1]. In recent modern therapies, the treatments for PMOP, such as hormone replacement therapy, is applied to the prevention of osteoporosis in postmenopausal women.
Authors Authors and affiliations P.D. Miller N. Pannacciulli J. Malouf-Sierra A. Singer E. Czerwiński H.G. Bone C. Wang S. Huang A. Chines W. Lems J.P. Brown Original Article First Online: 28 November 2019 Shares 226 Downloads Abstract Summary Transitioning postmenopausal women with osteoporosis from a bisphosphonate to denosumab appears to be safe and more effective at improving BMD than continuing treatment with a bisphosphonate.
P.D. Miller, DDS Abstract: Published more than three decades ago, the original classification of marginal tissue recession described four classes of recession. For example, in Miller Class III recession, there were different scenarios in which complete root coverage could not be achieved. Today, however, newer surgical techniques have made it possible for clinicians to potentially achieve complete root coverage when interdental bone loss exists.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.